Earnings Call · Q1 FY2024·2024-05-13

Q1 24EPS +2.27%·Rev n/aQ4 23EPS +6.98%·Rev n/aQ3 23EPS +11.36%·Rev n/aQ2 23EPS +13.64%·Rev n/a⚠ consensus missing

Fulcrum Therapeutics, Inc. FULC

Alexander Sapir — Chief Executive Officer

Alan Musso — Chief Financial Officer

−1.6%1d on move date−1.6% vs SPY3d+10.4%5d+1.1%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more FULC calls or request research access.

More FULC calls Browse calls Request research access